Find verified Ceftobiprole medocaril sodium API manufacturers, suppliers, and distributors across the globe. Explore companies that offer high-purity Ceftobiprole medocaril sodium for pharmaceutical use, along with product details, certifications, and reliable sourcing options. Compare prices, check availability, and connect directly with trusted suppliers for Ceftobiprole medocaril sodium API.
Alternate Names: Ceftobiprole medocaril, Ceftobiprole medocaril sodium salt, BAL5788
CAS No: 376653-43-9
PubChem CID: 135413544
Mol Formula: C26H26N8O11S2
Mol Weight: 690.7 g/mol
IUPAC Name: (6R,7R)-7-[[(2Z)-2-(5-amino-1,2,4-thiadiazol-3-yl)-2-hydroxyiminoacetyl]amino]-3-[(E)-[1-[(3R)-1-[(5-methyl-2-oxo-1,3-dioxol-4-yl)methoxycarbonyl]pyr -Show More
Therapeutic use: Antibiotics
Drug Class: Beta-lactams, Cephalosporins
Commercial / Development Status: Commercial APIs
Source / Manufacturing Origin: Semi-synthetic APIs
API Description: Ceftobiprole medocaril is a prodrug of [ceftobiprole], a fifth-generation semisynthetic cephalosporin antibacterial. Ceftobiprole is a broad-spectrum agent with demonstrated activity against both Gram-positive and Gram-negative bacteria, including antibiotic-resistant strains of Staphylcoccus aureus (methicillin-resistant Staphylococcus aureus; MRSA). The EMA's Committee for Medicinal Products for Human Use (CHMP) adopted a negative opinion of ceftobiprole medocaril in February 2010, recommending the refusal of its marketing authorization in the European Union primarily due to data quality issues in pivotal clinical studies. It received its first approval in Canada in October 2017 for use in certain patients with bacterial pneumonia, and was subsequently approved in the United States with additional indications for skin and skin structure infections and bacteremia in April 2024.
